COMPANION MEETINGS Hans Popper Hepatopathology Society   Sunday, February 27, 2011 — 8:30 a.m., CC 103 A/B   Evidence- Based Liver Biopsy Practice   Moderator: David E. Kleiner, Laboratory of Pathology and National Cancer Institute, Bethesda, MD   Disclosure: In accordance with ACCME guidelines regarding disclosure, the USCAP policy requires that faculty members who have a significant financial or other relationship with a commercial company, entity, or service (which will be discussed in this Symposium) must disclose this to attendees. The Academy also requires that speakers disclose any products that are not labeled for the use under discussion. The speakers listed below have indicated they have nothing to disclose. Click the button above to add this event to your Itinerary Planner... 8:30 Evidence-Based Evaluation of Chronic Liver Disease - Zachary Goodman, Inova Fairfax Hospital, Falls Church, VA 9:15 The Liver Biopsy in Modern Clinical Practice: A Pediatric Point-of-View - Joel Lavine, Columbia University/ Morgan Stanley Children's Hospital, New York, NY 10:00 Break 10:30 Evidence-Based Evaluation of Liver Transplant Pathology - Emma E. Furth, Hospital of the University of Pennsylvania and University of Pennsylvania Health Systems, Philadelphia, PA 11:15 The Biopsy for 'Cirrhosis' - Elizabeth M. Brunt, Washington University School of Medicine, St. Louis, MO This topic was chosen by the Executive Committee of the Hans Popper Hepatopathology Society based on the need to continually re-evaluate the utility of the liver biopsy in modern clinical practice. The liver biopsy has been an effective tool for evaluation of the liver for decades with its major role primarily being that of diagnosis. Advances in laboratory diagnostics and imaging have led to changes in the liver biopsies role, reports now include information regarding the severity of the disease and the presence of unsuspected diagnoses. The objectives of this symposium are: 1) To highlight aspects of the liver biopsy that continue to provide real diagnostic value to the clinician. 2) To recognize liver biopsy findings that have a proven role in making therapeutic decisions and in prognostication. A clinical colleague will provide a perspective on the liver biopsy from the pediatric hepatologist's point-of-view.